ID: ALA1836348

Max Phase: Preclinical

Molecular Formula: C21H30ClN3O4

Molecular Weight: 387.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(CC(=O)O)N1Cc2ccc(NC(=O)CCCC3CCNCC3)cc2C1=O.Cl

Standard InChI:  InChI=1S/C21H29N3O4.ClH/c1-14(11-20(26)27)24-13-16-5-6-17(12-18(16)21(24)28)23-19(25)4-2-3-15-7-9-22-10-8-15;/h5-6,12,14-15,22H,2-4,7-11,13H2,1H3,(H,23,25)(H,26,27);1H

Standard InChI Key:  MVAPRARLGZLDBX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 387.48

Molecular Weight (Monoisotopic): 387.2158

AlogP: 2.61

#Rotatable Bonds: 8

Polar Surface Area: 98.74

Molecular Species: ZWITTERION

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.61

CX Basic pKa: 10.36

CX LogP: -0.90

CX LogD: -0.90

Aromatic Rings: 1

Heavy Atoms: 28

QED Weighted: 0.64

Np Likeness Score: -0.34

References

1. Krysko AA, Samoylenko GV, Polishchuk PG, Andronati SA, Kabanova TA, Khristova TM, Kuz'min VE, Kabanov VM, Krysko OL, Varnek AA, Grygorash RY..  (2011)  RGD mimetics containing phthalimidine fragment as novel ligands of fibrinogen receptor.,  21  (19): [PMID:21852128] [10.1016/j.bmcl.2011.07.063]

2. Krysko AA, Samoylenko GV, Polishchuk PG, Fonari MS, Kravtsov VCh, Andronati SA, Kabanova TA, Lipkowski J, Khristova TM, Kuz'min VE, Kabanov VM, Krysko OL, Varnek AA..  (2013)  Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.,  21  (15): [PMID:23757209] [10.1016/j.bmc.2013.05.019]

Source

Source(1):

• Scientific Literature